Ubiquigent Limited, a company focused on enabling and supporting ubiquitin system-focused drug discovery, announced that it had entered into an agreement with Dorian Therapeutics to provide access to one of its novel small molecule libraries specifically designed to target deubiquitylase (DUB) enzymes.

Data analysis and clinical trial software specialist, Exploristics, has announced a £1m government innovation loan from Innovate UK and the appointment of Chris Molloy as its non-executive chairman following a period of significant growth.

More than 150 leading scientific suppliers and 3,000 attendees will descend on Lab Innovationson 30& 31October2019 at the NEC,Birmingham,to  discover,  debate  and  discuss  the  latest  scientific  developments  and equipment.

Veratrak, a UK-based software provider dedicated to transforming supply chains across the life science industry, has announced that contract packaging organisation (CPO) Central Pharma has selected its platform to help it achieve digitised end-to-end visibility of its supply chain and improve collaboration.

The Annex 1 of the EU GMP Guide "Manufacture of Sterile Medicinal Products" is considered the most important European regulatory standard for the manufacture of sterile pharmaceutical products.

EMC Szpitale augments Clinerion’s patient coverage in Poland by joining the Patient Network Explorer platform. Patients at the hospital group will gain greater access to clinical trials, and actively support in accelerating the successful launch of innovative medical treatments.

Elligo Health Research, an integrated research organization (IRO), announces the launch of its innovative IntElligo Research Stack™ clinical technology.

BIOTEM, a key player in the development of monoclonal antibodies of excellence, is pleased to announce the launch of a collaboration with CALIXAR, an innovative company specialized in the isolation and production of native and functional membrane proteins (MP).

Biologics offer new therapy options for numerous diseases: They are already used to treat cancer and autoimmune diseases such as rheumatoid arthritis as useful alternatives to standard therapies.

The Czech Clinical Research Institute (CCRI) will support patients and physicians in the Czech Republic and Slovakia in accessing innovative treatments by expanding Clinerion’s hospital and patient coverage into those countries.

Pfizer has revealed new Phase 2 data on its 20-valent pneumococcal conjugate vaccine candidate, known as PF-06482077 (20vPnC)

Biokin Pharmaceutical Co. Ltd. a leading pharmaceutical company with operations in China and U.S., and Cryoport, Inc. , the world's leading temperature-controlled logistics company dedicated to the life sciences industry.

STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – and Dizal Pharmaceutical, a biotechnology company, announce a strategic partnership. Under the terms of the collaboration.

Vetter, a global operating Contract Development and Manufacturing Organization (CDMO) announced that a significant level of expansion activities are nearing completion at its US clinical manufacturing facility located at the Illinois Science & Technology Park in suburban Chicago.

Encube Ethicals, an integrated pharmaceutical organisation specialising in topical, transdermal and complex delivery solutions, has announced that its new high potency manufacturing facility for topical formulations is now fully operational.

Thermo Fisher Scientific Inc. today announced the opening of a state-of-the-art packaging and distribution facility in Ahmedabad to better serve pharmaceutical customer growth in India and their increasing need for clinical trial support focused on local products for India’s market.

Clariant, a focused and innovative specialty chemical company, announced the launch of a new standard tube/desiccant stopper product, created and sized to serve the needs of the Vietnam market.

SkyCell is introducing a comprehensive insurance against product loss called “Peace of Mind Insurance”.

In order to eliminate the risk of product loss for its clients, the Swiss-based manufacturer of the world’s safest temperature-controlled containers for pharmaceuticals is providing a hassle-free insurance add-on with coverage of up to US$ 4 Million per container. Backed by a multinational commercial insurance company, SkyCell is the only provider of pharma containers to offer such a defacto temperature performance guarantee for the transport of temperature-sensitive pharmaceuticals.

Common practice today is that all players in the pharma supply chain – freight forwarders, airlines and packaging companies exclude any financial responsibility in case of temperature excursion. This leaves all the risk with the pharma manufacturer. SkyCell’s new “Peace of Mind Insurance” add-on closes this gap.

“We want to give all our clients a peace of mind when shipping their sensitive pharmaceuticals and to stop worrying about temperature excursions. On top of providing them with the safest pharma containers in the market, our “Peace of Mind Insurance” systematically eliminates the financial impact of product loss,” said Richard Ettl, CEO of SkyCell. It’s impeccable and audited track record enables SkyCell to get coverage of up to US$ 4 Million product value per container.

With the award-winning and quality audited performance of its temperature-controlled pharma containers, SkyCell is constantly pushing for innovation and better services for its clients. For every shipment, SkyCell experts use the SkyCell Transport Planner’s risk assessment to define lane SOPs together with the shipper, freight forwarder and airlines, producing a comprehensive lane risk analysis even for shipments to remote destinations. “Our SkyCell Transport Planner helps us to identify the risks, mitigate them and insure them. With our new insurance offering, we want our clients not to have the slightest doubt about the safe transport of their valuable cargo anymore. This is an absolute novelty in our business” said Marrie Groeneveld, Chief Commercial Officer at SkyCell.

SkyCell’s outstanding quality was just recently verified by one of the Big Four international audit companies. In their study, the auditors scrutinized and audited all SkyCell shipment results of the last 12 months. According to the results of the study, temperature excursions happened only during 0.1 percent of the transports with a SkyCell container.


SkyCell is a leading manufacturer of temperature-controlled containers for pharmaceuticals, offering the safest logistics service within the pharmaceuticals industry. 14 of the 20 largest pharmaceutical manufacturers globally have independently validated the service offering of SkyCell and implemented its usage into their supply chain. In only six years, SkyCell became the fourth largest container company and has the largest fleet of Internet of Things plugged-in containers in the world for the shipment of temperature controlled pharmaceutical products by air.

About SkyCell:SkyCell is the 4th largest pharma airfreight container provider with the mission to supply the safest pharma containers worldwide. This is achieved through the unique combination of hardware, software and service, enabling our clients to master logistical challenges and eliminate temperature excursion.

14 of the top 20 pharma companies have tested and verified SkyCell as the safest solution on the market, with less than 0.1% temperature deviations since launch. The efficient insulation and cutting-edge cooling technology enable the containers to keep the temperature for 160h+. All containers are equipped with IoT sensors, leading to a seamless supply chain through global tracking and monitoring. Based in Switzerland and with a global service station network, SkyCell is serving pharma companies around the world. For more information visit www.skycell.ch